Estrella Immunopharma Inc. (ESLA) — Cash Flow-to-Debt Ratio
Estrella Immunopharma Inc. (ESLA) has a Cash Flow-to-Debt Ratio of -0.75x as of March 2026, meaning its operating cash flow of $-6.70 Million could theoretically repay -1% of its total liabilities ($8.93 Million) in one year. Explore ESLA cash flow metrics to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Estrella Immunopharma Inc. Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for Estrella Immunopharma Inc. across 5 annual periods. Also explore how large is Estrella Immunopharma Inc.'s balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Estrella Immunopharma Inc. (2021–2025)
Year-by-year debt coverage analysis for Estrella Immunopharma Inc.. For market capitalisation and broader financial context, see Estrella Immunopharma Inc. (ESLA) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.13x | $-1.79 Million | $13.54 Million | ▲ +94.8% |
| 2024 | -2.55x | $-7.64 Million | $3.00 Million | ▲ +97.1% |
| 2023 | -88.92x | $-16.07 Million | $180.70K | ▼ -24738.1% |
| 2022 | -0.36x | $-1.04 Million | $2.92 Million | ▼ -48.0% |
| 2021 | -0.24x | $-1.44 Million | $5.96 Million | — |